A framework for real‐time glycosylation monitoring (RT‐GM) in mammalian cell culture
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Glycosylation is a critical characteristic of biotherapeutics because of its central role in in vivo efficacy. Multiple factors including medium composition and process conditions impact protein glycosylation and characterizing cellular response to these changes is essential to understand the underlying relationships. Current practice typically involves glycosylation characterization at the end of a fed‐batch culture, which in addition to being an aggregate of the process, reflects a bias towards the end of the culture where a majority of the product is made. In an attempt to rigorously characterize the entire time‐course of a fed‐batch culture, a real‐time glycosylation monitoring (RT‐GM) framework was developed. It involves using the micro sequential injection (μSI) system as a sample preparation platform coupled with an ultra‐performance liquid chromatography (UPLC) system for real‐time monitoring of the antibody glycan profile. Automated sampling and sample preparations were performed using the μSI system and this framework was used to study manganese (Mn)‐induced glycosylation changes over the course of a fed‐batch culture. As expected, Mn‐supplemented cultures exhibited higher galactosylation levels compared to control while the fucosylation and mannosylation were consistent for both supplemented and control cultures. Overall, the approach presented in the study allows real time monitoring of glycosylation changes and this information can be rapidly translated into process control and/or process optimization decisions to accelerate process development. Biotechnol. Bioeng. 2015;112: 1146–1154. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393 · cited 2×
“The enhancement of complement activation has been correlated with an increase in galactosylation of antibodies (Hodoniczky et al., 2005; Raju, 2008; Tsuchiya et al., 1989) and an enhanced anti-inflammatory effect with increased sialylation (Kaneko et al., 2006; Scallon et al., 2007).”
BackgroundIsotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
Cited by
Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing
Jiang, M., Severson, K. A., Love, J. C., Madden, H., Swann, P., Zang, L., & Braatz, R. D. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26383 · Cited by 118
Toward Biotherapeutic Product Real‐Time Quality Monitoring
Guerra, A., von Stosch, M., & Glassey, J. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1524362 · Cited by 58
“can achieve less sample consumption [12].”
BackgroundInfluentialSha, S., & Yoon, S. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.03.020 · Cited by 20
Computational tools for predicting and controlling the glycosylation of biopharmaceuticals
Kontoravdi, C., & Jimenez del Val, I. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.08.007 · Cited by 18
Metadata
- Authors
- Tharmalingam, T., Wu, C., Callahan, S., & T. Goudar, C.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2015-04-17
- Volume
- 112
- Issue
- 6
- Pages
- 1146-1154
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2119616127
- Cited by
- 58
- References
- 3
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.